HY-P990452 Search Results


sacituzumab  (MedChemExpress)
94
MedChemExpress sacituzumab
Knockdown of Trop2 expression by NB60 E and cell viability against LTLT-Ca cells. ( A ) Cell lines expressing Trop2, namely, MDA-MB-468 and letrozole-resistant MCF-7 (LTLT-Ca), were checked for Trop2 expression by Western blot. Expression was compared relative to the control cells HEK293t, which do not express Trop2. ( B ) Respective cell lines were treated with either HEK293T E or NB60 E for 48 h. After EVs treatment, protein lysates were collected and ran for Western blot. Trop2 knockdown was compared to the control, the cells not treated with the respective EVs. ( C ) LTLT-Ca cells were seeded onto a 96-well plate and were treated for 48 h with varying concentrations of the respective EVs. After treatment of cells with the indicated concentrations of EVs, MTT assay was performed to determine the viability of the cells. ( D ) LTLT-Ca cells were seeded into 100 mm tissue culture dishes and were treated for 48 h with either <t>Sacituzumab</t> (Sac) or NB60 E. After treatment, the cells were collected, and protein lysates were prepared for Western blot. Trop2 expression was probed to compare knockdown of the said antibodies in LTLT-Ca cells. Cells that were not treated with either Sac or NB60 E served as the control group. (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001).
Sacituzumab, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sacituzumab/product/MedChemExpress
Average 94 stars, based on 1 article reviews
sacituzumab - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


Knockdown of Trop2 expression by NB60 E and cell viability against LTLT-Ca cells. ( A ) Cell lines expressing Trop2, namely, MDA-MB-468 and letrozole-resistant MCF-7 (LTLT-Ca), were checked for Trop2 expression by Western blot. Expression was compared relative to the control cells HEK293t, which do not express Trop2. ( B ) Respective cell lines were treated with either HEK293T E or NB60 E for 48 h. After EVs treatment, protein lysates were collected and ran for Western blot. Trop2 knockdown was compared to the control, the cells not treated with the respective EVs. ( C ) LTLT-Ca cells were seeded onto a 96-well plate and were treated for 48 h with varying concentrations of the respective EVs. After treatment of cells with the indicated concentrations of EVs, MTT assay was performed to determine the viability of the cells. ( D ) LTLT-Ca cells were seeded into 100 mm tissue culture dishes and were treated for 48 h with either Sacituzumab (Sac) or NB60 E. After treatment, the cells were collected, and protein lysates were prepared for Western blot. Trop2 expression was probed to compare knockdown of the said antibodies in LTLT-Ca cells. Cells that were not treated with either Sac or NB60 E served as the control group. (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001).

Journal: Pharmaceutics

Article Title: Engineered Nanobody-Bearing Extracellular Vesicles Enable Precision Trop2 Knockdown in Resistant Breast Cancer

doi: 10.3390/pharmaceutics17101318

Figure Lengend Snippet: Knockdown of Trop2 expression by NB60 E and cell viability against LTLT-Ca cells. ( A ) Cell lines expressing Trop2, namely, MDA-MB-468 and letrozole-resistant MCF-7 (LTLT-Ca), were checked for Trop2 expression by Western blot. Expression was compared relative to the control cells HEK293t, which do not express Trop2. ( B ) Respective cell lines were treated with either HEK293T E or NB60 E for 48 h. After EVs treatment, protein lysates were collected and ran for Western blot. Trop2 knockdown was compared to the control, the cells not treated with the respective EVs. ( C ) LTLT-Ca cells were seeded onto a 96-well plate and were treated for 48 h with varying concentrations of the respective EVs. After treatment of cells with the indicated concentrations of EVs, MTT assay was performed to determine the viability of the cells. ( D ) LTLT-Ca cells were seeded into 100 mm tissue culture dishes and were treated for 48 h with either Sacituzumab (Sac) or NB60 E. After treatment, the cells were collected, and protein lysates were prepared for Western blot. Trop2 expression was probed to compare knockdown of the said antibodies in LTLT-Ca cells. Cells that were not treated with either Sac or NB60 E served as the control group. (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001).

Article Snippet: The following day, cells were treated with Sacituzumab (Cat. #HY-P999045, MedChemExpress, Princeton, NJ, USA) at concentrations of 50, 100, or 200 nM, or with NB60 E at particle concentrations of 1 × 10 10 or 1 × 10 11 particles/mL.

Techniques: Knockdown, Expressing, Western Blot, Control, MTT Assay